FDA indicates Biohaven Pharmaceuticals‘ Nurtec ODT for the acute treatment of migraine with or without aura in adults.
The agency recently extended the indication to include the preventive treatment of migraines.
Nurtech is currently the only drug to win FDA approval as both an acute and preventive migraine treatment. The expanded indication has launched the drug into “the next stage of being really disruptive,” according to Biohaven Pharmaceuticals’ CEO Vlad Coric.
Filed Under: Neurological Disease
Tell Us What You Think!
You must be logged in to post a comment.